Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice - PubMed (original) (raw)
. 1998 Oct 1;161(7):3639-44.
Affiliations
- PMID: 9759887
Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice
I K Campbell et al. J Immunol. 1998.
Abstract
The involvement of granulocyte-macrophage CSF (GM-CSF) in collagen-induced arthritis (CIA) was examined using GM-CSF-deficient mice. Although CIA is generally considered to be restricted to mice of the H-2q or H-2r haplotypes, we examined the role of GM-CSF in the CIA model using GM-CSF-deficient (-/-) and wild-type (+/+) mice on a C57BL/6 (H-2b) background. Mice were immunized by intradermal injection at the base of the tail with chick type II collagen followed by a repeat injection 21 days later. We found, based on both clinical and histologic assessments, that wild-type mice on this background developed severe CIA, while the GM-CSF-deficient mice had virtually no disease. Mice that were heterozygous for the GM-CSF gene (+/-) collectively displayed an intermediate response between those of the GM-CSF(+/+) and GM-CSF(-/-) groups, suggesting a gene dosage effect. GM-CSF(+/+) and GM-CSF(+/-) mice exhibited CIA responses ranging from mild (single digits) to severe swelling of all four paws, while in the few GM-CSF(-/-) mice that developed CIA the disease was confined to single digits. Despite the putative role of GM-CSF in dendritic cell development, GM-CSF-deficient mice exhibited both humoral and cellular (delayed-type hypersensitivity) responses to type II collagen; however, the cellular response was significantly reduced in the GM-CSF-deficient mice compared with the wild-type controls. These findings suggest that GM-CSF is required for CIA development in mice and support the idea that GM-CSF is a key cytokine in inflammatory joint disease.
Similar articles
- Reduced susceptibility to collagen-induced arthritis in mice deficient in IFN-gamma receptor.
Kageyama Y, Koide Y, Yoshida A, Uchijima M, Arai T, Miyamoto S, Ozeki T, Hiyoshi M, Kushida K, Inoue T. Kageyama Y, et al. J Immunol. 1998 Aug 1;161(3):1542-8. J Immunol. 1998. PMID: 9686622 - Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model.
Plater-Zyberk C, Joosten LA, Helsen MM, Koenders MI, Baeuerle PA, van den Berg WB. Plater-Zyberk C, et al. Ann Rheum Dis. 2009 May;68(5):721-8. doi: 10.1136/ard.2007.085431. Epub 2008 May 21. Ann Rheum Dis. 2009. PMID: 18495731 - Collagen-induced arthritis in rodents: a review of immunity to type II collagen with emphasis on the importance of molecular conformation and structure.
Cremer MA, Kang AH. Cremer MA, et al. Int Rev Immunol. 1988 Sep;4(1):65-81. doi: 10.3109/08830188809044771. Int Rev Immunol. 1988. PMID: 3072386 Review. No abstract available.
Cited by
- Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Fleischmann RM, van der Heijde D, Strand V, Atsumi T, McInnes IB, Takeuchi T, Taylor PC, Bracher M, Brooks D, Davies J, Goode C, Gupta A, Mukherjee S, O'Shea C, Saurigny D, Schifano LA, Shelton C, Smith JE, Wang M, Wang R, Watts S, Weinblatt ME. Fleischmann RM, et al. Ann Rheum Dis. 2023 Dec;82(12):1516-1526. doi: 10.1136/ard-2023-224482. Epub 2023 Sep 12. Ann Rheum Dis. 2023. PMID: 37699654 Free PMC article. Clinical Trial. - Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
Taylor PC, Weinblatt ME, McInnes IB, Atsumi T, Strand V, Takeuchi T, Bracher M, Brooks D, Davies J, Goode C, Gupta A, Mukherjee S, O'Shea C, Saurigny D, Schifano LA, Shelton C, Smith JE, Wang M, Wang R, Watts S, Fleischmann RM. Taylor PC, et al. Ann Rheum Dis. 2023 Dec;82(12):1527-1537. doi: 10.1136/ard-2023-224449. Epub 2023 Sep 11. Ann Rheum Dis. 2023. PMID: 37696589 Free PMC article. Clinical Trial. - GM-CSF receptor/SYK/JNK/FOXO1/CD11c signaling promotes atherosclerosis.
Tsukui D, Kimura Y, Kono H. Tsukui D, et al. iScience. 2023 Jul 11;26(8):107293. doi: 10.1016/j.isci.2023.107293. eCollection 2023 Aug 18. iScience. 2023. PMID: 37520709 Free PMC article. - Intra-articular delivery of AAV vectors encoding PD-L1 attenuates joint inflammation and tissue damage in a mouse model of rheumatoid arthritis.
Li W, Sun J, Feng SL, Wang F, Miao MZ, Wu EY, Wallet S, Loeser R, Li C. Li W, et al. Front Immunol. 2023 Mar 3;14:1116084. doi: 10.3389/fimmu.2023.1116084. eCollection 2023. Front Immunol. 2023. PMID: 36936967 Free PMC article. - Treatment with Granulocyte-Macrophage Colony-Stimulating Factor Reduces Viral Titers in the Brains of West Nile Virus-Infected Mice and Improves Survival.
Stonedahl S, Leser JS, Clarke P, Potter H, Boyd TD, Tyler KL. Stonedahl S, et al. J Virol. 2023 Mar 30;97(3):e0180522. doi: 10.1128/jvi.01805-22. Epub 2023 Feb 21. J Virol. 2023. PMID: 36802227 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases